ArticleCureus2025
Perioperative Use of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Lower Readmission Rates After Coronary Artery Bypass Grafting (CABG) in Adults With Congenital Heart Disease.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- GLP-1 Receptor Agonists in Cardiac Surgery: From Metabolic Drug to Potential Perioperative Cardioprotective Agent.Journal of cardiovascular development and disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Glucagon-like peptide-1 (GLP-1) receptor agonists (RA) are increasingly prescribed for type 2 diabetes and obesity, with emerging evidence of cardiovascular benefits. However, their impact on postoperative outcomes in adult congenital heart disease (CHD) patients undergoing coronary artery bypass grafting (CABG) remains underexplored. Methods We conducted a retrospective cohort study using de-identified patient data from the TriNetX Research Network from 2005 to 2025. Adult CHD patients (International Classification of Diseases, 10th Revision (ICD-10) codes Q20-Q28) who underwent CABG (Current Procedural Terminology (CPT) codes 1006208, 1006217, 1006200) were divided into two cohorts: those with documented perioperative GLP-1 RA use, defined as use within three months prior to or one month after CABG (Anatomical Therapeutic Chemical (ATC) code A10BJ), and those with no documented GLP-1 RA use (control cohort). Propensity score matching (1:1) was used to balance the cohorts based on race, ethnicity, sex, age at surgery, comorbidities (including diabetes, obesity, and heart failure), and CHD diagnoses. Primary outcomes included one-year all-cause mortality and hospital readmission rates. Secondary outcomes included GLP-1-related complications (acute pancreatitis, gastroparesis, abnormal weight loss) and postoperative events (acute kidney injury (AKI), myocardial infarction (MI), transient ischemic attack (TIA), cerebral infarction, arrhythmia, and hypoglycemic events). Results A total of 720 patients were included after 1:1 propensity score matching; 360 patients remained in each group (GLP-1 RA users vs control). Baseline characteristics, including age, sex, and key comorbidities, were well balanced. GLP-1 RA use was associated with a significantly lower one-year hospital readmission rate (odds ratio (OR) = 0.68;
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.